Alnylam Pharmaceuticals Inc at Citi BioPharma Conference (Virtual) Transcript
Hi, everyone. Welcome to our fireside chat with Alnylam, and I'm pleased to have with me today Jeffrey Poulton, CFO of Alnylam. Jeff, thanks for joining us for the session.
It's great to be here, Joel. Thanks a lot. I've been with Alnylam for about a year now as the CFO. Very excited about the company and its prospects. It's the leading RNAi company in the space. It's been at it since 2002 in developing this technology. And today, it's a multiproduct global commercial company. 2 commercial products today, potentially 2 more commercial products by the end of the year, 1 which would be our product to commercialize, and 1 inclisiran in the hands of Novartis. More than 10 products in the clinic and a true platform company in terms of the ability to invest in itself organically and drive long-term growth and value. So a very well-positioned company, very interesting, excited
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
